NMR Investigations of the Static and Dynamic Structures of Bisphosphonates on Human Bone: a Molecular Model

Sujoy Mukherjee,† Yongcheng Song,‡ and Eric Oldfield*†,‡

Center for Biophysics and Computational Biology, 607 South Mathews Avenue, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, Department of Chemistry, University of Illinois at Urbana-Champaign, 600 South Mathews Avenue, Urbana, Illinois 61801

Received August 9, 2007; E-mail: eo@chad.scs.uiuc.edu

Abstract: We report the results of an investigation of the binding of a series of bisphosphonate drugs to human bone using 2H, 13C, 15N, and 31P nuclear magnetic resonance spectroscopy. The 31P NMR results show that the bisphosphonate groups bind irrotationally to bone, displacing orthophosphate from the bone mineral matrix. Binding of pamidronate is well described by a Langmuir-like isotherm, from which we deduce an ∼30–38 Å2 surface area per pamidronate molecule and a ∆G = −4.3 kcal mol−1. TEDOR of [13C3, 15N] pamidronate on bone shows that the bisphosphonate binds in a gauche [N−C(1)] conformation. The results of 31P as well as 15N shift and cross-polarization measurements indicate that risedronate binds weakly, since it has a primarily neutral pyridine side chain, whereas zoledronate (with an imidazole ring) binds more strongly, since the ring is partially protonated. The results of 2H NMR measurements of side-chain 2H-labeled pamidronate, alendronate, zoledronate, and risedronate on bone show that all side chains undergo fast but restricted motions. In pamidronate, the motion is well simulated by a gauche/gauche hopping motion of the terminal −CH2−NH3+ group, due to jumps from one anionic surface group to another. The results of double-cross polarization experiments indicate that the NH3+-terminus of pamidronate is close to the bone mineral surface, and a detailed model is proposed in which the gauche side-chain hops between two bone PO4−3 sites.

1. Introduction

Bisphosphonate drugs such as pamidronate (1, Aredia), risedronate (2, Actonel), zoledronate (3, Zometa) and alendronate (4, Fosamax) are used to treat a variety of bone resorption diseases, such as osteoporosis, Paget’s disease, and hypercalcemia due to malignancy.1 They are thought to act by inhibiting the enzyme farnesyl diphosphate synthase,2 resulting in inhibition of protein prenylation in osteoclasts. In addition to their use in treating these diseases, bisphosphonates have also been found3 to activate γδ T cells (containing the Vγ2Vδ2 T cell receptor) of the immune system, which then kill tumor cells;4 plus, they have direct activity against tumor cell growth,5 as well as the growth of a variety of pathogenic protozoa6 and some bacteria.7 There is thus interest in studying in more detail how bisphosphonates bind to human bone, since this could have important implications for their future development in oncology and as anti-infectives, where, in general, bone binding might be expected to reduce efficacy.

In recent work, several groups have used chromatographic and other methods to investigate how bisphosphonates bind to hydroxyapatite,8–10 one component of bone mineral. However, because bone contains ∼25–40% protein11 (mainly collagen)
and because there are only relatively low levels of hydroxyapatite present in the mineral phase, (the major component is carbonatoapatite), it is clearly of interest to probe in a more direct fashion how bisphosphonates bind to human bone. Moreover, chromatographic methods give no direct information on either the static or the dynamic structures of bound bisphosphonates, or information on their protonation states. It is likewise unclear whether binding is primarily a physisorption process, or involves displacement of phosphate groups by the anionic bisphosphonate ligands. Here, we thus report the results of a series of liquid- and solid-state NMR investigations of the interactions between bisphosphonates and human bone. Solid-state NMR is an ideal technique with which to investigate the structures (static and dynamic) of molecules bound to bone surfaces, and has previously been used to investigate the structures of bone mineral,12,13 as well as of a bone-seeking peptide, statherin, interacting with hydroxyapatite.14 We show that bisphosphonates bind tightly to human bone (displacing PO4 3−); that their sidechains exhibit restricted mobility; that protonation states can be observed directly, and that, in the case of pamidronate, the bound drug conformation can be determined experimentally, leading to a detailed molecular model for pamidronate-bone binding.

2. Materials and Methods

2.1. NMR Spectroscopy. Solid-state NMR spectra were obtained by using the magic-angle sample spinning technique using 600 MHz (H resonance frequency) Infinity Plus spectrometers (Varian, Palo Alto, CA) equipped with 14.1 T, 2.0 and 3.5 in. bore Oxford magnets and Varian/Che magnetics 3.2 and 4.0 mm T3 HXY probes. For 13C and 31P experiments, spectra were obtained by using cross-polarization and with TPPM16 decoupling. Proton decoupled solid-state 31P spectra were recorded with and without (for quantitation) cross-polarization while liquid-state spectra were acquired with full proton decoupling. For pamidronate, a two-dimensional 13C–15N correlation spectrum was obtained by using radio frequency driven recoupling (RFDR).16 A heteronuclear, broadband double cross polarization (DCP) experiment17 was performed for 13C–15N HNMR experiments, spectra were obtained by using cross-polarization and with TPPM16 decoupling. Proton decoupled solid-state 13C spectra were recorded with and without (for quantitation) cross-polarization, while liquid-state spectra were acquired with full proton decoupling. For pamidronate, the bound drug conformation can be determined experimentally, leading to a detailed molecular model for pamidronate-bone binding.

2.2. Synthetic Radiolabeled Bisphosphonates. 2.2.1. General Procedure: A mixture of a carboxylic acid (1 mmol), H3PO3 (5 mmol) and toluene (4 mL) was heated to 80 °C with stirring. After all solids melted, POCl3 (5 mmol) was added slowly and the mixture stirred vigorously at 80 °C for 5 h.23 Upon cooling, the toluene was decanted, and 6 N HCl (3 mL) was added to the residue. The resulting solution was stirred for 6 h, after which most of the solvent was removed in vacuo. Isopropanol (25 mL) was added to precipitate a 1-hydroxy-methylene bisphosphonate as a white powder, which was filtered, washed with ethanol (5 × 5 mL), dried, and then further purified by recrystallization from H2O/EtOH. All compounds had satisfactory C, H, N microanalyses and 1H solution NMR spectra.

2.2.1.1. 1-Hydroxy-3-aminopropyl-1,1-bisphosphonic Acid-13C3,15N (Pamidronic Acid-13C3,15N). This compound was made from [13C3,15N] β-alanine (Cambridge) (250 mg), following the above general procedure (205 mg, 45%).

2.2.1.2. 1-Hydroxy-3-aminopropyl-1,1-bisphosphonic Acid-2,2,3,3-2H4 (Pamidronic Acid-d4). This compound was made from β-alanine-2,2,3,3-2H4 (C/D/N Isotopes, Quebec, Canada) (250 mg), following the above general procedure (225 mg, 50%).

2.2.1.3. 1-Hydroxy-4-aminobutyl-1,1-bisphosphonic Acid-2,2,3,3,-2H4 (Alendronic Acid-d4). This compound was made from [2,2,3,3,4,4,2H4]-4-aminobutyric acid (Aldrich) (250 mg), following the above general procedure (210 mg, 47%).

2.2.1.4. 1-Hydroxy-2-(15N2)-imidazol-1-yl-1,1-bisphosphonic Acid (15N2-zoledronic Acid). This compound was made from [15N2]-imidazole-1-acetic acid, which was prepared according to a published procedure25,26 from [15N]-imidazole (Cambridge) (260 mg), following the above general procedure (265 mg, 26%).

2.2.1.5. 1-Hydroxy-2-([2,4,5,6-2H4]-pyridin-3-yl)ethylidene-1,1-bisphosphonic Acid- (Risedronic Acid-d3, [2,4,5,6-3H3]-3-Pyridinylacetic acid was prepared according to a published procedure27 from [2,4,5,6-3H3]-3-bromopyridine,28 followed by hydrolysis (1 N DCl, reflux), [2,4,5,6-3H]-risedronic acid was made from the acid obtained (137 mg) following the above general procedure (185 mg, 65%).

2.2.2. Preparation of Bisphosphonate-Bone Samples. Human bone tissue (non-demineralized bone powder, gun-shot victim, 45–125 μm particle size,) was obtained from the Pacific Coast Tissue Bank (Los Angeles, CA) and was used without further treatment. Typically, 50

ng of bone powder was suspended in 1 mL H2O and the bisphosphonate was dissolved in 1 mL of H2O. The pH of both samples was adjusted to the pH of interest, and the samples were then mixed, and the pH adjusted (with concentrated NaOH or HCl) as needed. Samples were incubated for 1 h and centrifuged, after which the supernatant was removed. The bone-bisphosphonate pellets were then washed with 2 mL of Millipore water and packed into NMR rotors. In some cases, the supernatant solutions were also investigated by solution NMR using an external NaH2PO4 quantitation standard (doped with 10 µM FeCl3).

3. Results and Discussion

3.1. Chemisorption of Bisphosphonates to Bone. In Figure 1A–D, we show the 31P MAS NMR spectra of three different bisphosphonates: zoledronate (3), pamidronate (1), and deoxy-risedronate (5), bound to human bone at pH = 7 together with, inset, the 31P MAS NMR spectra of the pure bisphosphonates. In each case, the bone spectra consist of two sets of resonances (and their associated side-bands): a sharp feature at ~3 ppm corresponding to orthophosphate in the bone mineral, and a second, broader and weaker feature at ~15 ppm, due to the bisphosphonate bound to bone. The bisphosphonate peak is featureless, unlike those seen in the spectra of the corresponding crystalline bisphosphonates, and has essentially the same width and shift at 105, 104, and 103 ppm loadings, disappearing into the noise level at ~100 ppm (Figures 2A–D) No other peaks were observed. These observations are similar to those made by Josse et al.,29 who found that zoledronate (3) bound to a variety of calcium phosphate compounds (β-tricalcium phosphate; calcium-deficient apatites), of interest as novel biomaterials for drug delivery, with a relatively broad, featureless line shape.29 The lack of any discernible structure would, however, be consistent with either physisorption or chemisorption. That is, the bisphosphonates might undergo either relatively weak electrostatic interactions with the inorganic components of bone, together with hydrophobic interactions with the collagen component, or they might be involved in the displacement of anionic groups (OH−, CO32−, and PO43−), with the bisphosphonate PO3 groups substituting for these anions in the lattice. And, of course, both types of interaction might occur. The “chemical” displacement interaction might be expected to be more likely, because bisphosphonates are known to have half-lives in bone on the order of many years; plus, this displacement mechanism would give at least a qualitative explanation of the observation that high levels of PO32− are required to elute bisphosphonates from hydroxyapatite in chromatographic adsorption experiments.8 The NMR results support several aspects of this strong chemisorption model. First, the overall spans of the chemical shielding tensors are ~120 ppm, similar to those seen in crystalline bisphosphonates,30 indicating no significant motional averaging of the chemical shift anisotropy. If only physisorption were involved, then considerable narrowing the 31P spectral width would seem likely, due to fast motion on the bone surface. Second, an analysis of the supernatants in our experiments by solution 31P NMR shows that there is, in fact, release of inorganic phosphate on bisphosphonate addition with, on average, ~1.25 bisphosphonates binding per phosphate released, essentially the same effect as that seen with the synthetic calcium phosphate compounds investigated by Josse et al.29 So, bisphosphonates bind in an irrotational manner to bone (or, at least, these are no fast, large-angle motions of the bisphosphonate backbone), and this can be attributed, at least in part, to displacement of inorganic phosphate by at least one phosphate group, enabling strong bisphosphonate interactions with Ca2+ in the bone mineral matrix.

Interestingly, the area of the bisphosphonate surface peak observed does not correlate in a linear way with the amount of bisphosphonate added to the sample. Rather, our results indicate that binding exhibits the type of sigmoid binding behavior seen with chemisorption, as expected for example by the Langmuir-

---

Figure 1. 31P MAS NMR spectra (600 MHz 1H resonance frequency) of bisphosphonates bound to bone (A–D) together with (inset), spectra of the corresponding crystalline bisphosphonates. All spectra were obtained by using cross-polarization followed by TPPM decoupling during data acquisition. (A) zoledronate on bone, 2 s recycle, 8192 scans and 10 kHz spin speed; (B) pamidronate on bone, 5 s recycle, 1024 scans and 13.333 kHz spin speed; (C) deoxy-risedronate on bone, 2 s recycle, 16384 scans and 10 kHz spin speed; and (D) pamidronate on bone, 2 s recycle, 4096 scans and 8 kHz spin speed. All FIDs were processed with 50 Hz line broadening.
like binding isotherm for the reaction:

\[
BP\text{(solution)} + S \xrightleftharpoons[k_1]{k_2} BP\cdot S \text{(bound)}
\]

where \(BP\) = bisphosphonate, \(S\) = bone surface, and the surface coverage, \(\theta\), is given by the following:

\[
\theta = K[c]/(1 + K[c])
\]

where \([c]\) is the concentration of bisphosphonate in solution and \(K = k_1/k_2\). At low \([c]\), \(\theta \approx [c]\), whereas in the limit \([c] \to \infty\), \(\theta = 1\). The binding of the salivary protein statherin to HAP has also been shown to follow Langmuir-binding behavior, 31 from which information on the thermodynamics of binding can be deduced. We thus obtained \(^{31}\)P MAS NMR spectra of pamidronate bound to bone at eight concentrations (representative spectra are shown in Figures 2A–D), then plotted the relative bisphosphonate: bone area versus the amount of BP (pamidronate) used and fitted the data to a rectangular hyperbolic function, Figure 2E [the Y axes are bound pamidronate (left) and \(\theta\) (right), respectively]. The graph can be calibrated by using our observation that the addition of 2.7 mg pamidronate results in 1.41 mg of bisphosphonate being bound per 50 mg bone sample, from which we deduce that the maximum coverage corresponds to 4.68 mg of bound pamidronate. Given that the mineral component of human bone has a surface area area of \(\sim 110 \text{ m}^2/\text{gram}\) \(^{32,33}\) and that \(\sim 60\%–75\%\) of bone is composed of this mineral component, \(^{31}\) we can deduce a surface area of pamidronate on bone as: 

\[
(\text{bone mineral surface area in sample})/\text{(number of pamidronate molecules bound)} = (110 \text{ m}^2/\text{gram} \times 0.05 g \times (0.6–0.75) \times 10^{20} \text{Å}^2)/ (6.023 \times 10^{23} \times 0.00468 \text{ g/mol} \times (\text{Na}^+\text{pamidronate} \times \text{H}_2\text{O} \text{Fwt}) \sim 30–38 \text{ Å}^2 \text{molecule. This value is close to that of the 40 Å}^2\text{molecule that can be deduced from the unit cell dimensions of monosodium pamidronate,}^{34}\text{ and indicates that pamidronate molecules are quite highly packed on the mineral component of human bone, at high coverage, although as shown in Figure 1B, the}^{31}\text{P MAS NMR spectra of crystalline pamidronate are of course quite different. From the isotherm, we obtain} \Delta G = -4.3 \text{ kcal mol}^{-1}\text{ for pamidronate binding to human bone mineral.}

This type of chemisorption is only seen at pH \(= 7\), and without any pH control, we find that a separate bisphosphonate phase can form. For example, addition of the free zwitterionic risedronic acid to bone (in H\(_2\)O) results in the appearance of new resonances at \(\delta = 15.0, 16.1\) ppm, the same as seen in a sample of Ca\(^{2+}\)-risedronate prepared by adding Ca(NO\(_3\))\(_2\) to risedronate at low pH. X-ray powder diffraction of such samples at high bisphosphonate loading reveals sharp diffraction peaks that are the same as those found in Ca\(^{2+}\)-risedronate, indicating formation of a new nanocrystalline phase, due to displacement of bone Ca\(^{2+}\). This result is similar to that observed by Josse et al.\(^{39}\) on zoledronate addition to a calcium phosphate phase, but seems unlikely to be of physiological relevance. So, the results of Figure 2 support the idea that, at pH \(\sim 7\), bisphosphonate chemisorbs to human bone mineral surface, forming, at high concentrations, a monolayer.

In addition to displacing P, and interacting with Ca\(^{2+}\), there is also now evidence for the importance of the 1-OH group on the bisphosphonate backbone in binding to hydroxyapatite,\(^{8}\) as well as the importance of side chain charge and location.\(^{9}\) This is evidenced by differences in the affinity for hydroxyapatite in chromatographic experiments by, e.g., zoledronate and risedronate,\(^{8}\) whose side chains have different pK\(_A\) values, as well as by \(^{31}\)P NMR results, on bone. At pH = 4.0, the pyridine ring in risedronate is protonated, since the pK\(_A\) value of the pyridine ring is \(\sim 5.7\), and this protonation enables the ready cross-polarization of \(^{15}\)N-risedronate bound to bone, as shown in Figure 3A. The \(^{31}\)P MAS NMR spectrum also indicates strong bone binding, as seen in Figure 3B. At pH = 6.0, however, the \(^{15}\)N NMR cross polarization peak intensity is much weaker (about the same as the intensity arising from the \(^{15}\)N-sites in collagen),\(^{5}\) Figure 3C, although the \(^{31}\)P peak from the chemisorbed bisphosphonate is still pronounced (Figure 3D). This is consistent with a decrease in bone adsorption due to the fact that the pyridine ring nitrogen is now (on average) far less protonated than that at pH = 4.0. At pH = 8.0, the pyridinium \(^{15}\)N peak is no longer detectable (Figure 3E) although the surface


bisphosphonate peak is still observable (Figure 3F) but is clearly less intense than that at the lower pH values. Clearly, these 15 N and 31 P NMR results indicate that side-chain deprotonation is associated with weaker bone binding. In the case of [15 N 2]-zoledronate bound to bone at pH 7.0, the 15 N MAS NMR spectrum (Figure 3G) is more intense than that seen with risedronate at either pH 6 or 8, consistent with the fact that the imidazole side chain of zoledronate is expected to have a \( pK_a \) 6.7 and is, therefore, more highly protonated, resulting in increased cross polarization as well as enhanced electrostatic interactions with anionic groups on the bone surface. On the basis of integrated 31 P CP-MAS NMR peak areas, we find that pamidronate and zoledronate bind most strongly to human bone (28.7, 23% bisphosphonate: bone peak areas), followed by ortho-risedronate (6), risedronate (2) and deoxy-risedronate (5) on HAP obtained by column chromatography versus the ratio of the bisphosphonate/bone 31 P peak areas; \( R^2 = 0.88 \).

3.2. Static and Dynamic Structures of Bound Bisphosphonates. We thus next investigated the structures (static and/or dynamic) of several bisphosphonates bound to bone. We elected to begin by investigating the static and dynamic structure of pamidronate (I, Aredia), since this is the simplest nitrogen-containing bisphosphonate drug and can be readily prepared as the [13 C, 15 N]-labeled isotopomer from commercially available [13 C 3]â-alanine. The 1D 13 C CP-MAS NMR spectrum of [13 C 3, 15 N]-pamidronate is shown in Figure 4A, and consists of the resonance of C1 (J-coupled to P1 and P2) at 73 ppm, with of bound bisphosphonates might of course be guessed from \( pK_a \) values alone, this approach clearly does not work with bisphosphonates bound to their target FPPS enzyme, where both risedronate and zoledronate bind in a fully protonated state (at pH 7.0), even though there are no obvious nearby proton sources present in the active site, warranting therefore these 15 N NMR experiments on bone. But what are the structures—static and dynamic, of these adsorbed bisphosphonates?

Figure 3. 15 N and 31 P MAS NMR of bisphosphonates on bone. (A–F), 15 N (A, C, E) and 31 P (B, D, F) MAS NMR spectra of [15 N]-risedronate on bone at the pH values indicated. (G) 15 N MAS NMR spectrum of [15 N 2]-zoledronate on bone, pH = 7.0. The natural abundance level 15 N signals from collagen are indicated. At pH = 7.0, there is a small resonance from N3 of the neutral imidazole side chain, at 245 ppm. Spectra were typically obtained by using a 3.8 8 s pulse, a mix pulse of 6 ms (15 N NMR) or 1 ms (for 31 P NMR), followed by data acquisition for 1024 points with a dwell time of 20 8 s. A pulse delay of 3 s (for 15 N) or 2 s (for 31 P) was used. FIDs were zero-filled to 2048 points and processed with 200 Hz (15 N NMR) or 50 Hz (31 P NMR) line-broadening prior to Fourier transformation. All 31 P NMR spectra were obtained with 8192 scans, while the 15 N spectra required from 65536 to 100 000 scans. (H) Comparison plot of retention times of bisphosphonates (zoledronate (3), ortho-risedronate (6), risedronate (2) and deoxy-risedronate (5) on HAP obtained by column chromatography versus the ratio of the bisphosphonate/bone 31 P peak areas; \( R^2 = 0.88 \).
the C(2), C(3) peaks to high field. These resonances can be unambiguously assigned from an RFDR spectrum (Figure 4B) with C(2) being the most highly shielded peak. When bound to bone, there is a substantial broadening of each resonance (Figure 4C); plus, there are additional small peaks observed. These arise from the glycine, alanine, proline, and hydroxyproline residues in collagen, as shown in Figure 4D. A difference spectrum ([bone + bisphosphonate] - bone) is shown in Figure 4E, and represents the spectrum of pamidronate alone, when bound to bone. The 13C(3) line width is small, but that of C(1) (the bisphosphonate backbone carbon) is larger, and that of C(2) is larger still. For C(1), much of the apparent broadening must arise from J-coupling to 31P (see Figure 3A), but this cannot contribute to the breadth of C(2). Rather, it seems that here, there is a chemical shift dispersion due, most likely, to gauche interactions with a heterogeneous population of phosphonate OH/O- groups. As expected, the 15N NMR spectrum contains only a single intense resonance, having a chemical shift of 36.5 ppm (from NH3), consistent with a fully protonated alkyl-ammonium group (Figure 4F). So, 13C and 15N MAS NMR spectra of pamidronate on bone can be readily obtained, opening up the possibility of determining the structure of this bisphosphonate, on human bone. To do this, we employed the z-filtered TEDOR method to determine the distances between C(1) and N, which give, in principle, the backbone conformation.

In crystalline sodium pamidronate, the bisphosphonate side chain adopts a close-to-trans C(1)-C(2)-C(3)-N configuration, but on bone, the conformation is unknown and could, in principle, be either a trans or a gauche configuration (gauche+ or gauche-), with the gauche conformations potentially facilitating electrostatic interactions between the terminal ammonium group in the bisphosphonate with anionic groups on the bone surface, due to its “bent” conformation. It also seemed possible that the side chain might actually be quite dynamic, jumping from one anionic bone surface site to another. To deduce the likely backbone conformation, we used the TEDOR experiment. We first investigated as a reference sample [13C3, 15N] labeled pamidronate, diluted (9%) into natural abundance pamidronate, and cocrystallized as the sodium salt (sample characterized via powder X-ray diffraction). In Na-pamidronate, the 154° (~trans) side-chain conformation corresponds to a 3.82

---

Figure 4. 13C and 15N MAS NMR spectra of [13C3, 15N] pamidronate. (A) 13C NMR spectrum of pamidronate acquired by using a 3 µs 90° pulse width, 2 ms mix time, 50 µs dwell time, 2048 points, 10 s recycle delay, 16 scans, and a 13.333 kHz spin speed. Spectrum was zero-filled to 4096 points and processed with 50 Hz line broadening. (B) 13C-13C RFDR correlation spectrum of [13C3, 15N] labeled pamidronate. (C)–(E) 13C NMR spectra of (C) pamidronate on bone; (D) bone; and (E) difference between (C) and (D). All 13C NMR spectra obtained using a 3 µs width 90° pulse, 2 ms mix time, 10 µs dwell time, 2048 points, 10 s recycle delay, 2048 scans and a 13.333 kHz spin speed. Data zero-filled to 4096 points and processed with 50 Hz line broadening. (F) 15N NMR spectrum of [13C3, 15N]-pamidronate on bone, 4 µs 90° pulse width, 5 ms mix time, 50 µs dwell time, 2048 points, 4 s recycle delay, 20 388 scans, and a 13.333 kHz spin speed. Data zero-filled to 4096 points and processed with 50 Hz line broadening.

---

5B), shown in Figure 5C. Of course, both gauche using the 1.59 Å TEDOR-derived C(3)–N bond length, ±71° using the 1.59 Å TEDOR-derived C(3)–N bond length, Figure 5B), shown in Figure 5C. Of course, both gauche\(^{+}\) and gauche\(^{-}\) conformers would be consistent with the NMR results and because the two forms are mirror images, neither would be preferred (and indeed, as discussed below, it appears that the two forms interconvert, via 2-site jumps). In any case, the TEDOR results strongly suggest that the pamidronate side chain minimizes its electrostatic interaction with the bone mineral surface (carbonatoapatite and hydroxypatite) via NH\(_3\) to enhance this interaction.

That is, the bisphosphonate side chain is “bent” over, in order to enhance this interaction.

Of course, the interactions of the bisphosphonate side chains with bone could be quite dynamic, even though the bisphosphonate backbones are not highly mobile. To investigate this possibility, we determined the \(^{3}\)H NMR spectra of side chain \(^{3}\)H-labeled pamidronate, alendronate, zoledronate, and risedronate, bound to bone. Reference \(^{2}\)H NMR spectra for each of the crystalline bisphosphonates were typically 100 s with \(^{10}\)~100 scans being acquired. The kinetic rate (sec\(^{-1}\)), conformer ratio, \(\eta\), QCC (kHz) and jump angles (degrees) were as follows: pamidronate, 3 × 10\(^{7}\), 1, 0.05, 175, ±65; alendronate, 5 × 10\(^{6}\), 1, 0.05, 167, ±60 (for both the side-chain torsion angles); zoledronate, 5 × 10\(^{6}\), 1, 0.068, 185, ±35; risedronate, 3 × 10\(^{6}\), 1, 0.05, 185, ±60; A 50% attenuation of the C\(^{6}\), C\(^{8}\) CH\(_2\) groups in alendronate was used to reflect their larger \(T_1\) values. In the case of zoledronate, the intensity used for \(^{3}\)H(5) was only 20%, due to \(^{3}\)H/\(^{1}\)H exchange during synthesis (based on 500 MHz solution \(^{3}\)H NMR).

\[\text{C}(1)-\text{N} \text{ distance.}\] The results of a TEDOR experiment on this magnetically dilute sample, Figure 5A, yielded a C(1)–N distance of 3.90 Å, in quite good accord with the crystallographic result (3.82 Å). In contrast, for pamidronate bound to the surface of human bone mineral, the TEDOR result (Figure 5B) yielded a C(1)–N distance, \(d = 3.2\) Å. This is clearly very short and translates to a close to gauche backbone conformation (\(\chi = ±77°\), using the 1.49 Å X-ray C(3)–N bond length; ±71° using the 1.59 Å TEDOR-derived C(3)–N bond length, Figure 5B), shown in Figure 5C. Of course, both gauche\(^{+}\) and gauche\(^{-}\)
mobility. We thus next performed 2 H NMR line shape changes (Figure 6I).

6E–H). However, at 30 °C, there are clearly spectral line shape changes (Figure 6I–L), indicating the presence of side chain mobility. We thus next performed 1H NMR line shape simulations for all four 4H labeled bisphosphonates on bone (at 30 °C), as shown in Figure 6M–P, in which the line shape simulations (in red) are superimposed on the experimental spectra (in black). The models used are shown in Figure 7A–D. In the case of pamidronate, the results of the TEDOR experiments indicated the likely existence of a gauche conformation, with a C(1)-N torsion angle of ±71–77° (gauche+, gauche–). As gauche+ and gauche– are equally energetically likely, this suggested a simple two-site model (Figure 7A) in which gauche+ and gauche– forms interconvert, and the results of a 2H line shape simulation in which the CH2–NH3+ group undergoes a 2-fold hop (±65°) between gauche+ and gauche– at ~3 x 107 s⁻¹, due perhaps to the CH2–NH3+ group sampling two different anionic binding sites, was found to be in good agreement with experiment (Figure 6M). In the case of alendronate, the line shape is very different from that seen with pamidronate, and closely resembles that seen previously in 1H NMR spectra of 4H labeled gel-state lipids, where the CH2 groups undergo fast but restricted two-site hopping. One possible motion for the alendronate side chain, shown in Figure 7B, would be a “mirror-image” jump in which all three CH2 groups undergo motional averaging. In this case, the NH3+ group remains in the same location, but there are coupled rotations at each site in the side chain and again, the results of a line shape simulation are in good agreement with experiment, Figure 6N. For zoledronate, we find good accord (Figure 6O) for a ±60° ring wobble (Figure 7C) and for risedronate, there is again evidence for restricted motion that freezes out at low temperatures (Figure 6H), with the results of a line shape simulation (Figure 6P) suggesting a ±60° ring wobble with a 1:4 conformer population, at 30 °C. While further work with, for example, specifically 3H labeled bisphosphonates, will be needed in order to obtain more detailed motional models, what is clear from the results of Figures 6 and 7 is that the side chains of each bisphosphonate undergo fast (but restricted) motions when bound to bone. In contrast, none of the crystalline bisphosphonates undergo fast side-chain motion, and all of the side chain motions on bone are frozen out at ~50 °C. In the case of pamidronate, fast gauche+/gauche– isomerization is indicated (at 30 °C) from the 2H NMR line shape simulation and is consistent with the TEDOR result (at 0 °C), which also indicates the presence of a gauche conformer. In this case, only the C-3 or γ-protons are affected, as illustrated in Figure 7E. For alendronate, the line shape is similar to that seen previously in gel state lipids, and suggests restricted tetrahedral jumps (e.g., between the “mirror-images” shown in Figure 7B). For zoledronate and risedronate, the situation is more complex, since both protonated and neutral rings could be present. However, there is clearly no evidence for rapid 180° ring flips in either zoledronate or risedronate, since these would be expected to result in η ~ 0.65 line shapes, as observed, e.g., for phenylalanine residues in proteins and in zwitterionic phenylalanine. This can of course be attributed to the presence of the basic

Figure 7. Models for bisphosphonates on bone depicting proposed side-chain motions: nitrogen = cyan; deuterium = yellow; carbon = gray; oxygen = red; phosphorus = pink. (A), pamidronate gauche+/gauche– side-chain motion leading to a backbone torsional oscillation of ~±65°; (B), alendronate undergoing tetrahedral or “mirror image” jump motion; (C), zoledronate undergoing ±30° ring wobbles and, (D), risedronate undergoing ±60° ring wobbles. With the exception of risedronate, all the side chains are shown protonated. (E), Schematic of pamidronate on bone depicting motional averaging model for 4H.

Figure 8. Molecular models for pamidronate-bone (HAP) interactions. (A), Top view of pamidronate bound in gauche+/gauche– conformations to a PO43− in one of the three 3P-triangles in the unit cell of HAP. (B, C), two views of pamidronate (carbon in brown; oxygen in red and hydrogen in cyan) side chain NH3+ (dark blue) binding to one or other of the PO43− (P = purple) groups (P2 or P3) in the “P3-triangle”, the bisphosphonate PO4 group occupies the third site (P1). The 1-OH group interacts with a Ca2+ (green) below. The 3C17−3PO43− distance is much shorter than the 3C17−3PO43− and 1C−3PO43− distances and the two conformations and interactions shown are consistent with the TEDOR, 4H and DCP NMR results.

nitrogen atoms in both bisphosphonates, which can interact electrostatically or via hydrogen bonds, with bone surface groups.

3.3. Molecular Model for Pamidronate on Bone. Finally, we propose a detailed molecular model for pamidronate binding to the mineral component of human bone at pH = 7 at 300 K. As can be seen from the results presented above, there are numerous pieces of the puzzle that need to be assembled. Pamidronate binds in a chemisorption process, releasing ~1 inorganic phosphate per bisphosphonate bound, and this process follows a classical first-order Langmuir isotherm, from which we deduce a surface area per pamidronate of 

\[ 1272 \text{ J. AM. CHEM. SOC.} \]

as shown in Figure 8B.C. This packing arrangement gives an immediate explanation for the presence of a gauche side chain configuration, because in this conformation, the terminal \( ^+\text{NH}_3 \) group can interact electrostatically with either one of the two remaining \( \text{PO}_{4}^{3-} \) groups (\( \text{P}_2/\text{P}_3 \)) in the "P$_3$-triangle", as shown in Figure 8B.C. The conformations of the side chains are either gauche$^+$ or gauche$^-$, and on the \( ^2\text{H} \) NMR results, we propose that these conformations can rapidly interconvert, at 30 °C. The model also reveals that the \( \text{I-OH} \) group is adjacent to a \( \text{Ca}^{2+} \), explaining the importance of this group for bone binding since a sizable ion-dipole interaction would be expected. To try to further test this model, we carried out a double cross-polarization experiment (\( ^1\text{H} \rightarrow ^{13}\text{C} \rightarrow ^{31}\text{P} \)) on \([^{13}\text{C}_1, \ ^{15}\text{N}]\) pamidronate on bone: the result is shown in Figure 9. As can be seen in the Figure, there is a major cross-peak between the \( ^{13}\text{C}^\text{R-} \) and \( ^{31}\text{PO}_{4}^{3-} \) bone mineral peaks, a smaller cross-peak between \( ^{13}\text{C}^\text{C}\text{ and } ^{31}\text{PO}_{4}^{3-} \), but no observable cross-peak between \( ^{13}\text{C}^\text{O} \) and bone mineral. The \( ^{13}\text{C}^\text{R-} \) cross-peak volume is by far the largest and is consistent with the short (average) \( ^{13}\text{C}^\text{O} \text{-} ^{31}\text{PO}_{4}^{3-} \) distance of ~3.03 Å found from the model (Figure 8), whereas the \( ^{13}\text{C}^\text{R-} \) and \( ^{13}\text{C}^\text{O} \text{-} ^{31}\text{PO}_{4}^{3-} \) distances are clearly much longer, ~3.75 and 3.9 Å, respectively. These results therefore strongly support a "bent-over" side chain conformation in which the \( ^+\text{NH}_3 \) group interacts with the bone surface, consistent with the TEDOR and \( ^2\text{H} \) NMR results which indicate gauche$^+$/ gauche$^-$ side-chain conformations.

4. Conclusions

In summary, the results discussed above can be viewed together to provide the first detailed spectroscopic picture of how bisphosphonates bind to human bone. First, and independent of any molecular model of binding, bisphosphonate

Figure 9. Double cross-polarization spectrum (\( ^1\text{H} \rightarrow ^{13}\text{C} \rightarrow ^{31}\text{P} \)) of \([^{13}\text{C}_1, \ ^{15}\text{N}]\) pamidronate on human bone. The experiment was performed at a spinning speed of 10 kHz with a \( ^1\text{H} \) 90° pulse width of 3.5 μs, a \( ^1\text{H} \rightarrow ^{13}\text{C} \) mix time of 0.8 ms followed by \( t_1 \) evolution, a \( ^{13}\text{C} \rightarrow ^{31}\text{P} \) mix time of 6 ms followed by data acquisition using 2048 points and a dwell time of 10 μs. Power levels for the \( ^{13}\text{C} \rightarrow ^{31}\text{P} \) transfer were matched to \( \omega_{C}= (5/2)\omega_R \) and \( \omega_{P}=(7/2)\omega_R \) in order to facilitate a broadband transfer covering all the peaks of interest in both dimensions. The indirect dimension was sampled with 64 real points (TPPI$^+$) with a dwell time of 20 μs and 2048 scans were acquired per row with a recycle delay of 2 s. TPPM decoupling of ~80 kHz (6 μs and 16° phase shifted) was used during chemical shift evolution and acquisition periods while ~75 kHz CW decoupling was used during the \( ^{13}\text{C} \rightarrow ^{31}\text{P} \) transfer. Two such experiments with a total acquisition time of ~6 days were added before processing. The cross-peak volume for \( ^{13}\text{C}^\text{R-} \) is large and indicates close proximity between \( ^{13}\text{C}^\text{R-} \) and bone \( ^{31}\text{PO}_{4}^{3-} \) groups. There are only small or no significant cross-peak volumes for \( ^{13}\text{C}^\text{C} \text{-} ^{31}\text{PO}_{4}^{3-} \), due to longer (3.75, 3.90 Å) \( ^{13}\text{C} \)–\( ^{31}\text{P} \) distances as compared to \( ^{13}\text{C}^\text{O} \text{-} ^{31}\text{PO}_{4}^{3-} \) (3.03 Å, on average, from the models shown in Figure 8).
backbones bind to bone in a “rigid” or rotational manner, at least on the time scale of the inverse of the $^{31}$P chemical shielding tensor anisotropy ($\sim \mu s$). That is, the overall breadths of the $^{31}$P shielding tensors in crystalline bisphosphonates are very similar to those found for bisphosphonates on bone, and there is no evidence for fast surface diffusion, which would be expected to average the CSA. Second, we find that inorganic phosphate is released when bisphosphonates bind to bone, indicating a displacement mechanism in which the bisphosphates are “chemically” bonded to the bone matrix. This would be consistent with the observation that high levels of $P_i$ are needed for the chromatographic elution of bisphosphonates from HAP. Third, we find that pamidronate binding can be well described by a Langmuir adsorption isotherm, that the surface area/pamidronate is $\sim 30-38 \, \AA^2$ and that $\Delta G$ for binding is $\sim -4.3 \, \text{kcal mol}^{-1}$ (at $pH = 7, 30 \, ^\circ C$). Fourth, the results of $^{15}$N NMR measurements indicate that zoledronate binds in a “partially” protonated form at $pH \, 7$, risedronate is non-protonated, while pamidronate is essentially fully protonated, consistent with known $pK_a$ values for imidazole ($pK_a \approx 6.7$), pyridine ($pK_a \approx 5.7$) and primary amines ($pK_a \approx 10.5$). Fifth, the results of TEDOR experiments show that pamidronate binds in a close-to-gauche conformation, which suggests that the terminal ammonium group might bind in such a way as to maximize its electrostatic interactions with anionic groups in the bone mineral. Sixth, the results of $^2$H NMR measurements indicate that pamidronate undergoes fast conformational changes ($3 \times 10^7 \, \text{sec}^{-1}$) on bone, interconverting most likely between gauche$^+$ and gauche$^-$ conformers. In contrast, alendronate undergoes a series of coupled rotations, yielding lineshapes and linewidths very similar to those seen previously with $^2$H-labeled lipids. With the aromatic bisphosphonates, there are rapid ($\sim 3 - 5 \times 10^4 \, \text{sec}^{-1}$) ring “wobbles”, although we find no evidence for the $\eta \approx 0.65$ lineshapes seen with aromatic groups (i.e., phenylalanine) in proteins, in which 2-fold 180° ring-flips occur. Seventh, the results of a double cross-polarization experiment indicate that the pamidronate side chain C$^\circ$ carbon is close to bone mineral PO$_4^{3-}$ groups, while C$^9$ and C$^{10}$ carbons are more distant. Overall, these results enable the construction of a molecular model for pamidronate binding to bone in which the chemisorbed bisphosphonate displaces one bone PO$_4^{3-}$ in the hydroxyapatite (carbonatoapatite) triangle of PO$_4^{3-}$ groups, enabling the gauche conformers (from TEDOR) to interconvert (from $^2$H NMR), jumping from one PO$_4^{3-}$ site to another (from DCP).

Given that bisphosphonates represent a large contribution to the global pharmaceutical market and that there is interest in their further development for use in oncology and as anti-infectives, the results presented above are of general interest in the context of tailoring new bisphosphonates to suit their intended application. In particular, the ability to begin to probe both the binding affinities ($\Delta G$, and in principle of course $\Delta H$ and $\Delta S$) as well as the static structures of bisphosphonates bound to human bone should help with the development of novel species that have particular attributes by using, for example, the types of structure-based design techniques used to develop enzyme inhibitors. For example, it has recently been shown that bisphosphonate activity in bone resorption in vivo can be well described by using a simple statistical model involving enzyme (FPPS) and HAP affinity data:

Acknowledgment. This work was supported by the United States Public Health Service (NIH Grant No. GM65307). S.M. was supported by an American Heart Association, Midwest Affiliate, Predoctoral Fellowship (Award Number 0615564Z). Y.S. was supported by a Leukemia and Lymphoma Society Special Fellowship (Award No. 3019-06). The authors would like to thank Professor Robert Griffin and Dr. Patrick van der Wel for providing the Turbopowder program, Professor Chad Rienstra, for helpful advice, and Dushyant Mukkamala, for help with the X-ray measurements.

JA0759949
